These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
529 related articles for article (PubMed ID: 19318323)
1. [Diagnostic difficulties in serous "borderline" tumors of the ovary]. Vereczkey I; Tóth E; Orosz Z Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323 [TBL] [Abstract][Full Text] [Related]
2. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045 [TBL] [Abstract][Full Text] [Related]
3. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Silva EG; Gershenson DM; Malpica A; Deavers M Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075 [TBL] [Abstract][Full Text] [Related]
4. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion. McKenney JK; Balzer BL; Longacre TA Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150 [TBL] [Abstract][Full Text] [Related]
5. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
6. Borderline epithelial tumors of the ovary. Hart WR Mod Pathol; 2005 Feb; 18 Suppl 2():S33-50. PubMed ID: 15761465 [TBL] [Abstract][Full Text] [Related]
7. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma. Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693 [TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Mayr D; Hirschmann A; Löhrs U; Diebold J Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438 [TBL] [Abstract][Full Text] [Related]
9. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Kennedy AW; Hart WR Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877 [TBL] [Abstract][Full Text] [Related]
11. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study. Sangoi AR; McKenney JK; Dadras SS; Longacre TA Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329 [TBL] [Abstract][Full Text] [Related]
12. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Prat J; De Nictolis M Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568 [TBL] [Abstract][Full Text] [Related]
13. Ovarian serous borderline tumors with invasive peritoneal implants. Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334 [TBL] [Abstract][Full Text] [Related]
15. Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838 [TBL] [Abstract][Full Text] [Related]
16. Clinical factors and biomarkers in ovarian tumors development. Vrabie CD; Petrescu A; Waller M; Dina I Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637 [TBL] [Abstract][Full Text] [Related]
17. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy]. Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214 [TBL] [Abstract][Full Text] [Related]
18. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Dehari R; Kurman RJ; Logani S; Shih IeM Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266 [TBL] [Abstract][Full Text] [Related]
19. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases. Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817 [TBL] [Abstract][Full Text] [Related]
20. [Serous micropapillary invasive carcinoma. Case report on both ovaries]. Espinosa de los Monteros Franco VA; Padilla Rodríguez AL Ginecol Obstet Mex; 2007 Nov; 75(11):682-6. PubMed ID: 18697443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]